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The human bowel contains a large and biodiverse bacterial community known as the microbiota or microbiome. It seems likely
that the microbiota, fractions of the microbiota, or speciﬁc species comprising the microbiota provide the antigenic fuel that
drives the chronic immune inﬂammation of the bowel mucosa that is characteristic of Crohn’s disease and ulcerative colitis. At
least twenty years of microbiological research have been expended on analysis of the composition of the bowel microbiota of
inﬂammatoryboweldiseasepatientsincomparisontothatofcontrolsubjects.Despiteextensivespeculationsabouttheaetiological
role of dysbiosis in inﬂammatory bowel diseases, knowledge that can be easily translated into eﬀective remedies for patients
has not eventuated. The causes of this failure may be due to poorly deﬁned and executed bacteriological studies, as well as the
overwhelming complexity of a biome that contains hundreds of bacterial species and trillions of bacterial cells.
1.Introduction
The large bowels of mammals comprise a biome (ecosystem)
that includes a bacterial community that is biodiverse and
numerous. It can be estimated that there are a total of twenty
trillion bacterial cells per human colon if it is assumed that
the colonic contents weigh on average about 200grams. The
majority of these bacteria are obligate anaerobes. They are
commonly referred to as commensals or symbionts because
they form long-lasting, interactive associations with their
animal hosts [1, 2]. These associations are generally regarded
to involve mutually beneﬁcial interactions, although some
commensals are opportunistic pathogens when appropriate
predisposing events occur [3]. The bacterial communities
(microbiota, microbiome) of human bowels contain pre-
dominantly representatives of four phyla: Actinobacteria,
Proteobacteria, Bacteroidetes,a n dFirmicutes (Table 1). The
Firmicutes and Bacteroidetes are numerically dominant in
the community. Numerous genera and species of bacteria
are represented in each of these broad phylogenetic groups
and, at least in the case of humans, there is person-to-person
variation in the composition of the bowel microbiota [4–
6]. Descriptions of a “normal range” of bowel inhabitants
of humans in terms of genera and species has recently
begun to emerge, sometimes referred to as the “core”
microbiota (5, 6; Table 2). The bowel microbiota is, like
bacterial communities in general, self-regulating and this
providestemporalstabilityincomposition.Atleastinhealth,
the proportions of broad phylogenetic groups of bacteria
within the community remain much the same over time
[4]. Inducible biochemical pathways that mediate hydrolysis
of exogenous (dietary plant cell wall polysaccharides) and
endogenous (mucins) substrates enable the bacteria to
obtain anuninterrupted supplyof carbonand energy despite
daily changes in the composition of the human diet [7, 8].
The fermentation of hydrolytic products by the bacteria
produces short chain fatty acids, amines, phenols, indoles,
and gases [9]. Knowledge of the nutritional niches of speciﬁc
bacterial groups is sparse but a detailed description and
importance of the butyrate-producing species in the ecology
of the bowel is emerging due to work at the Rowett Institute,
Scotland[10,11].Partitioningofbacteriawithinthecontents
of the bowel occurs. Some bacterial types are more likely to
be associated with particulate (plant residues) material in the
digestathanintheliquidfraction[12].Themucusassociated
with the mucosal surface has a layered conformation and
minimizes bacterial contact with the surface of enterocytes.
The outer mucus layer is loosely structured and contains
bacterialcellsthatareperhapslivingthereoraretrappedcells
that will eventually be swept away by the mucus ﬂow. The2 International Journal of Inﬂammation
inner mucus layer is dense and devoid of bacteria in healthy
people [13]. Nevertheless, bacteria-enterocyte signaling has
been demonstrated in laboratory animal models [14]. This
suggests that at least bacterial cell components or products
passthroughthemucusandreachreceptorsonthesurfaceof
enterocytes. These signaling events have been demonstrated
to aﬀectphysiologicalprocesseseveninsystemicorgans[15],
as well as aﬀecting mucosal immunology in which entero-
cytes and dendritic cells act as front-line mediators [16, 17].
Thus, the complex, numerous, and interactive microbiota
of the bowel cannot be overlooked in considerations of the
aetiology of inﬂammatory bowel diseases.
Crohn’s disease (CD) and ulcerative colitis (UC) are
chronic immune inﬂammatory conditions of the alimen-
tary tract referred to collectively as inﬂammatory bowel
diseases (IBD). There are strong genetic associations with
susceptibilitytoCDinparticular[18].Environmentalfactors
such as stress and diet are probably also important in the
aetiology of IBD, but remain poorly delineated [19]. CD
lesions can occur in upper regions of the alimentary tract
but are usually located where there are microbial residents
(ileum and colon), whereas UC is limited to the large bowel.
In both diseases, therefore, a case can be made that the sheer
antigenic load represented by trillions of bacterial cells will
have an important role in driving chronic inﬂammation of
the bowel mucosa [20, 21]. Experimental animal models of
colitis do not exactly mimic CD or UC but can be used to
examine the role of speciﬁc bacteria in the etiology of colitis
in general terms. The results of this work provide the clearest
evidence that bacteria resident in the bowel have an essential
role in the pathogenesis of colitis because, when maintained
germfree,theanimalsdonotdevelopdisease[22].Twomajor
reviews of publications relating to bacterial involvement in
inﬂammatory bowel diseases have been published recently
[23, 24]. Therefore this paper provides an appraisal of
current views rather than a deﬁnitive coverage of the whole
scientiﬁc literature.
2.Analysisof the Bowel Microbiota
Total microscope counts of the bacteria in human faces are
at least two-fold greater than colony counts obtained by
nonselectiveagarcultures[25].Experimentsusingmolecular
exclusion probes show that the majority of the bacterial
cells in feces are alive [26]. The results of nucleic acid-based
analytical methods applied to bulk DNA extracted from
stool or bowel samples (Table 3) have provided evidence
that the discrepancy between total and colony counts is
due to the presence of not-yet-cultivated bacteria [27].
In addition to providing a means of analysis of bacterial
communities containing noncultivable members, culture-
independent methods based on bacterial nucleic acids are
useful because faecal and other samples can be collected,
frozen, and dispatched to an analytical laboratory that
may be far distant from the location in which the human
subjects reside. Bacterial culture, on the other hand, requires
that samples be processed without freezing within a few
hours of collection. Thus, nucleic acid-based analyses of
the bowel microbiota have held sway during the past two
decades and have enabled extensive phylogenetical analysis
of bowel communities to be made [6, 28]. The major
weakness of nucleic acid-based analytical methods, however,
is that they do not diﬀerentiate between DNA from bacteria
that are actually active members of the community and
transients or relatively inactive cells; DNA sequences from
dead, quiescent, and metabolically active bacterial cells are
all detected by methods based on the extraction of bulk
DNA from human faeces [29]. Further, bacterial metage-
nomic sequences garnered from the bowel biome show the
metabolic potential of the microbiota and its phylogenetic
composition, but cannot reveal the temporal changes in
expression of bacterial genes in the bowel, although this will
be achievable through metatranscriptomics studies [8, 28].
While culture-independent studies have been indispensable
in modern microbial ecological studies and have yielded
a vast amount of information about the phylogeny and
metabolic potential of the bowel microbiota, there is a need
to return to culture-dependent studies. Such studies have
been largely abandoned in recent times because so many of
the bacterial inhabitants of the bowel were considered to be
unculturable. New enrichment culture methods hold hope
that the so far uncultivated bacteria will soon be cultured.
Culture of bowel bacteria that have speciﬁc metabolic or
antigenic properties would greatly enhance gene knockout
or transgenic, gnotobiotic animal studies. Ranking bowel
bacteria in terms of proinﬂammatory potential might be a
worthwhile exercise and could probably only be achieved
with cultivated species in combination with in vitro or in
vivo immunological systems. The immune system of CD
and UC patients has been clearly shown to be dysregulated
and that this is associated with mutations in distinct genetic
loci [20, 21]. Therefore, the balance between the bacterial
inhabitantsofthebowelandthemucosalimmunesystemhas
to be considered to be diﬀerent to that prevailing in healthy
subjects. This assumption must underpin all considerations
of the role of the bowel microbiota in inﬂammatory bowel
diseases.
3.Confounding FactorsinAnalysisof
the Microbiota
Bacteriological analysis of the bowel microbiota is fraught
with several diﬃculties that often confound valid interpre-
tation of results.
3.1. Sampling. Bacterial communities in stool reﬂect the
bacteriology of the rectum and do not oﬀer much ecological
knowledge of other regions of the digestive tract [30].
Mucosal biopsies, unlike stool, provide samples collected
from regions of the intestinal tract where inﬂammation
occurs. They are not perfect specimens for bacteriological
analysis, however, because they consist of only a few mil-
ligrams of tissue and have been collected from subjects that
have usually undergone bowel cleansing prior to endoscopy.
Residual bowel cleansing solution pools in the large bowel
and can be collected by aspiration. The aspirate, essentiallyInternational Journal of Inﬂammation 3
Table 1: Common terms used in bowel microbial ecology.
Phylogeny The history of organismal lineages as they change through time. It implies that
diﬀerent species arise from previous forms via descent, linking all forms of life.
Dysbiosis A term generally used in relation to the bowel biome indicating an imbalance in the
composition of the microbiota.
Firmicutes
Ap h y l u mo fbacteria, most of which have gram-positive cell wall structure. The
principal genera detected in human faeces are Clostridium, Eubacterium,
Anaerostipes, Coprococcus, Dorea, Lachnospira, Roseburia, Faecalibacterium,
Ruminococcus, Subdoligranulum,a n dCoprobacillus.
Bacteroidetes A phylum of bacteria that have gram-negative cell wall structure. The principal
genera detected in human faeces are Bacteroides, Parabacteroides,a n dAlistipes.
Actinobacteria
A phylum of gram-positive bacteria that includes, amongst others, the genera
Biﬁdobacterium and Collinsella that are often detected as members of the bowel
microbiota of humans.
Proteobacteria A phylum of bacteria that includes Escherichia coli, a common facultatively
anaerobic species in the bowel.
Bacteroides-Prevotella
cluster
A broad phylogenetic classiﬁcation comprising gram-negative, anaerobic species
forming a major portion of the bowel microbiota.
Clostridial cluster XIVa. A broad phylogenetic classiﬁcation comprised of several genera and species of
gram-positive bacteria, not exclusively clostridia.
Clostridial cluster IV A broad phylogenetic classiﬁcation comprised of several genera and species of
gram-positive bacteria, not exclusively clostridia.
Enrichment culture
An understanding of the environmental conditions favored by an organism,
together with genetic clues about the microbe’s abilities is used to guide the design
of culture media and conditions.
Probiotic Live microorganisms which when administered in adequate amounts confer a
health beneﬁt on the host.
Prebiotic
A dietary supplement of nondigestible carbohydrate (inulin and
fructo-oligosaccharides are the best known) that can be metabolized by particular
bacteria in the human colon.
a faecal solution, bathes the mucosal surface of the intestine
andinalllikelihoodcontaminatesit,aswellascontaminating
the endoscope and its mechanical parts that collect the tissue
sample. Despite washing of the biopses immediately after
collection, the TTGE proﬁles of biopsy-, aspirate-, and faecal
bacteria have been reported to be highly (about 80% on
average) similar [31]. This result supports the view that
bacteria detected in association with biopsies are mostly
contaminants from a faecal solution (aspirate) that pools
in the bowel and bathes the mucosal surface after bowel
cleansing.
3.2. Individuality and Nationality of Subjects. The compo-
sition of bowel communities, as judged by the results of
stool and biopsy analysis, is individualistic, extending even
down to the level of bacterial strains [32, 33]. Adding to the
complexity of the situation, it has been shown that TTGE
proﬁles generated from bacteria associated with biopsies
were inﬂuenced by nationality of the donors: Mexican
biopsy-associated proﬁles could be diﬀerentiated from those
of Canadians [31]. This might be a particularly important
observation because Canada has the highest incidence and
prevalence of Crohn’s disease yet reported, whereas this dis-
ease is rare in Mexico [34, 35]. Thus, the bowel community
of Canadians may contain commensals critical to fueling
chronic immune inﬂammation, whereas most Mexicans
may lack them. It was noteworthy that TTGE proﬁles of
Canadians commonly contained DNA fragments originating
in members of the Bacteroidetes, a bacterial phylum that has
been detected more commonly in association with biopsies
of Crohn’s disease patients, as well as producing bowel
inﬂammation in an experimental animal model of colitis
[36, 37].
3.3. Choice of Subjects. Most studies involving bowel com-
mensals have been weak in terms of statistical power because
only small numbers of patients are studied [24]. Carefully
matched patients and controls need to be recruited, and
sampling of patients and controls on several occasions
would provide more reliable results. Previous or concurrent
therapeutic drugs administered to patients, although not
antimicrobial, may nevertheless alter bowel physiology, and
hence community composition, relative to that of controls.
4. The Bowel Microbiotaand Inﬂammation
There are several ways in which the microbiota might be
linked to Crohn’s disease or ulcerative colitis: the microbiota
as a whole could act as a surrogate pathogen; speciﬁc
members of the microbiota could be overt pathogens and
incite mucosal inﬂammation; changes in the proportions
of phylogenetic groups comprising the microbiota could4 International Journal of Inﬂammation
Table 2:Commonspeciesinhumanfaeces.Seventyﬁvebacterialspecieswith>1%genomesequencecoveragein>50%of124adulthumans.
After Qin et al. [6]
Faecalibacterium prausnitzii Bacteroides fragilis
Roseburia intestinalis Eubacterium biforme
Dorea formicigenerans Bacteroides eggerthii
Bacteroides vulgatus Streptococcus thermophilus
Clostridium sp Bacteroides capillosus
Bacteroides uniformis Holdemania ﬁliformis
Eubacterium hallii Clostridium leptum
Bacteroides sp. Prevotella copri
unknown sp Clostridium sp.
Coprococcus comes Bacteroides plebeius
Eubacterium rectale Butyrivibrio crossotus
Ruminococcus sp. Bacteroides coprocola
Dorea longicatena Bacteroides ﬁnegoldii
Bacteriodes xylanisolvens Clostridium bartlettii
Bacteroides sp. Clostridium sp.
Bacteroides sp. Escherichia coli
Ruminococcus torques Parabacteroides johnsonii
Bacteroides sp. Subdoligranulum variabile
Alistipes putredinis Bacteroides intestinalis
Collinsella aerofaciens Catenibacterium mitsuokai
Parabacteroides distasonis Clostridium bolteae
Eubacterium siraeum Biﬁdobacterium pseudocatenulatum
Bacteroides ovatus Anaerotruncus colihominis
Bacteroides sp. Biﬁdobacterium catenulatum
Bacteroides sp. Ruminococcus gnavus
Bacteroides thetaiotaomicron Bacteroides coprophilus
Bacteroides dorei Bacteroides pectinophilus
Parabacteroides merdae Gordonibacter pamelaeae gen. nov. sp.
Biﬁdobacterium longum subsp. infantis Clostridium asparagiforme
Ruminococcus obeum Clostridium nexile
Biﬁdobacterium adolescentis Blautia hansenii
Bacteroides caccae Clostridium scindens
Ruminococcus bromii Enterococcus faecalis
Ruminococcus lactaris Mollicutes bacterium
Eubacterium ventriosum Bryantella formatexigens
Coprococcus eutactus Clostridium methylpentosum
Akkermansia muciniphila
Bacteroides stercoris
Bacteroides cellulosilyticus
initiate or perpetuate the inﬂammation by providing a
pathogenic, antigenic fuel. Alternatively, changes in com-
position could remove members of the microbiota that
normally inure the mucosal immune system to the presence
of commensals in the bowel.
4.1. The Unaltered Microbiota Acts as a Surrogate Pathogen.
This hypothesis concerning the pathogenesis of inﬂam-
matory bowel diseases does not invoke changes to the
bacteriology of the bowel. It is supported by the observation
that the bacterial proﬁles associated with biopsies are not
diﬀerent between inﬂamed and noninﬂamed mucosa [36,
38]. In this proposition, genetic predisposition of patients
to abnormal permeability of the bowel mucosa allows entry
of commensal antigens into subepithelial tissues. Cells of
the immune system are activated as if infection by an
invasive pathogen had occurred. Impaired regulation of the
subsequent immune inﬂammation, again due to genetic
predisposition, results in a chronic immune inﬂammation;
the immune response is poorly regulated and the permeable
epithelium allows constant movement of antigens into the
tissue so as to resemble a continuing infection [39]. In thisInternational Journal of Inﬂammation 5
Table 3: Commonly used nucleic acid-based (culture-independent) analytical methods.
PCR/denaturing electrophoretic polyacrylamide gels (PCR/DGGE, PCR/TTGE)
DNA is extracted directly from faecal samples. Hypervariable gene sequences (most often 16S rRNA) are ampliﬁed using PCR primers that
anneal with conserved sequences that span the selected hypervariable regions. One of the PCR primers has a GC-rich 5  end (GC clamp)
to prevent complete denaturation of the DNA fragments during gradient gel electrophoresis. Using 16S rRNA gene sequences as example,
ampliﬁed fragments from diﬀerent types of bacteria and present in the PCR product are separated using polyacrylamide gel electrophoresis.
In DGGE (denaturing gradient gel electrophoresis), the double-stranded 16S fragments migrate through a polyacrylamide gel containing a
gradient of urea and formamide until they are partially denatured by the chemical conditions. The fragments do not completely denature
because of the GC clamp, and migration is radically slowed when partial denaturation occurs. Because of the variation in the 16S sequences
of diﬀerent bacterial species, chemical stability is also diﬀerent; therefore, diﬀerent 16S “species” can be diﬀerentiated by this electrophoretic
method. Similarly, in TTGE (temporal temperature gradient electrophoresis), the 16S sequences can be separated by gradually increasing
the temperature of the polyacrylamide gel during electrophoresis. Separation is achieved on the basis of diﬀering temperature stability of
the 16S fragments. These methods generate a proﬁle of the numerically predominant members of the bacterial community. Individual
fragments of DNA can be cut from DGGE/TTGE gels, further ampliﬁed and cloned, then sequenced. The sequence can be compared to
those in gene databanks in order to obtain identiﬁcation of the bacterium from which the 16S sequence originated. Depending on the
length of the sequence, identiﬁcation to at least bacterial genus can be made.
Fluorescent in situ hybridization/ﬂuorescence-activated cell sorting (FISH/FC)
DNA (oligonucleotide) probes target speciﬁc rRNA sequences (16S or 23S) within ribosomes to which they hybridize. The probes are 5 
labelled with a ﬂuorescent dye which permits both detection and quantiﬁcation of speciﬁc bacterial populations. Bacterial cells within
which hybridisation with a probe has occurred ﬂuoresce and hence can be detected and counted by epiﬂuorescence microscopy (preferably
automated) or ﬂuorescence-activated ﬂow cytometry. Continual reassessment of the speciﬁcity and coverage of FISH probes is essential in
order to update and conﬁrm their continuing speciﬁcity and hence reliability. This is because new 16S rRNA gene sequences are constantly
added to databases. Epiﬂuoresence microscopic detection is laborious and time consuming, and manual microscopic enumeration requires
careful attention by the operator. A lower detection limit of about 106 bacteria per gram of faeces can be achieved. An automated method
of counting ﬂuorescent bacterial cells has been developed by coupling ﬂuorescence microscopy to a computerized system of image analysis.
Usingthisautomatedcountingdevice,thelowerdetectionthresholdhasbeenestimatedtobe107 bacteriapergramoffaeces.Therefore,only
the more numerous members of the bacterial community can be detected. Nevertheless, identiﬁcation of individual bacterial cells, as well as
morphologicalandtopographicalinformationarevaluablecharacteristicsofﬂuorescencemicroscopy.Combinedwithﬂowcytometry,FISH
provides a high throughput quantitative and qualitative method of analysis. Flow cytometry combines quantitative and multiparametrics
analysis (size, internal granularity, ﬂuorescence signal). A lower threshold of detection of 0.4% relative to the total number of bacteria
determined with the universal bacterial probe EUB338 has been demonstrated.
Quantitative PCR
PCR primers and ﬂuorescent probes targeting nucleic acid sequences, usually 16S rRNA gene sequences, which are unique to particular
bacterial species, are used to quantify the speciﬁc sequences in DNA extracted from faeces. Real-time quantitative PCR can be used to
quantify speciﬁc populations or phylogenetic clusters using speciﬁc PCR primers and ﬂuorescent probes. Target sequences in DNA are
ampliﬁed and simultaneously quantiﬁed (as absolute number of copies, or relative amount when normalized to DNA input, or by reference
toadditionalnormalizinggenes).TheprocedurefollowsthegeneralprincipleofPCRbutitskeyfeatureisthattheampliﬁedDNAisdetected
as the reaction progresses in real time in contrast to standard PCR where the product of the reaction is detected at its end. Two common
methods for detection of products in real-time PCR are: non-speciﬁc ﬂuorescent dyes that intercalate with any double-stranded DNA, or
(2) sequence-speciﬁc DNA probes consisting of oligonucleotides that are labelled with a ﬂuorescent reporter which permits detection only
after hybridization of the probe with its complementary DNA target.
16S rRNA gene phylogeny
Older studies utilised PCR ampliﬁcation of 16S rRNA genes from bulk DNA extracted from faeces followed by cloning the 16S rRNA
gene sequences in a plasmid vector in an Escherichia coli host, prior to sequencing. More recently, high throughput bead/emulsion-based
sequencing of PCR-ampliﬁed DNA or random sequencing of DNA fragments derived from bacterial communities in faeces (metagenome)
hasbeenused.Theseapproachesprovidecataloguesoftheconstituentbacterialtypes(usuallybroadphylogeneticgroups)ofthecommunity
when analysed in relation to a databank of 16S rRNA gene sequences (such as the Ribosomal Database Project pyrosequencing pipeline
tools).
Metagenomics
A microbial community is studied in terms of its collective genomes. Nowadays, this approach involves shotgun genome methods to
sequence random fragments of DNA from microbes in a sample collected from a biome of interest. DNA is directly extracted from the
sample,isbrokenintosmallfragments,andportionsofthesefragmentsaresequenced.SearchesofDNAsequencedatabasespermitcollation
ofthesequencinginformationintermsof16SrRNAgenes(biodiversity),genesassociatedwithmetabolicpathwaysincludingtheirpotential
regulation, and cell structural molecules. This methodology can reveal novel and fundamental insights about the biodiversity and metabolic
impacts of microbial life in biomes.
Metatranscriptomics
Measuring the transcriptomics (gene expression) of microbial communities in the wild. RNA (which includes mRNA) is extracted directly
from samples. Ribosomal RNA, which forms the major portion of the total RNA is removed. Then, remaining RNA is converted to cDNA by
reverse-transcription PCR. Random sequencing of the cDNA reveals the transcripts produced in the ecosystem. This approach has mostly
been used with oceanic samples but application of the methodology to bowel samples is possible.6 International Journal of Inﬂammation
scenario, it is the antigens that pass to the subepithelial
tissues that are relevant, rather than phylogenetic issues. It
may be more useful to identify bacterial antigens against
which the immune cells of Crohn’s disease and ulcera-
tive colitis patients react rather than to determine shifts
in community composition. Knowledge of these antigens
might aid diagnosis, as in the case of the CBir1 ﬂagellin
against which Crohn’s disease patients with complicated
conditions produce high antibody titres, or be included in
assays useful in the development of anti-inﬂammatory drugs
[40].
4.2. Speciﬁc Members of the Microbiota Act as Overt Pathogens
a n dI n c i t eM u c o s a lI n ﬂ a m m a t i o n .The concentration of
enterobacteria in CD may be increased [24] and they may
be phenotypically diﬀerent from commensal Escherichia
coli. Darfeuille-Michaud et al. isolated E. coli from resected
chronic ileal lesions and from neoterminal ileum (with
and without CD recurrence) after surgery [41]. Many of
the isolates from diseased ileum adhered to Caco-2 cells.
These authors conﬁrmed, in a subsequent study, that an
adherent-invasive type of E. coli (reference strain LF82) was
speciﬁcally associated with ileal mucosa in some CD patients
[42].
Biﬁdobacterium animalis has been shown to be more
prevalentincoliticmice.Inthisstudy,thecolonicmicrobiota
of formerly germfree interleukin 10 (IL-10)-deﬁcient mice
that had been exposed to the faecal microbiota of speciﬁc-
pathogen-free animals was screened using PCR/DGGE. The
composition of the large bowel microbiota of IL-10-deﬁcient
mice changed as colitis progressed. DNA fragments originat-
ing from four bacterial populations (“Bacteroides sp.”, Biﬁ-
dobacterium animalis, Clostridium cocleatum, enterococci)
were more apparent in PCR/DGGE proﬁles of colitic mice
relative to noncolitic animals, whereas two populations were
less apparent (Eubacterium ventriosum,A c i d o p h i l u sg r o u p
lactobacilli). Speciﬁc DNA:RNA dot blot analysis showed
that biﬁdobacterial rRNA abundance increased as colitis
developed [43]. In a subsequent experiment, monoassocia-
tion of IL-10-deﬁcient mice with Biﬁdobacterium animalis
subspeciesanimalisresultedinbowelinﬂammation,thusful-
ﬁlling Koch’s postulates [44]. In this study, a bacterial species
belonging to a genus (Biﬁdobacterium) generally regarded
as harmless in the bowel and possibly even “beneﬁcial”,
was shown to have pathogenic potential in immunologically
dysregulated animals.
Chronic or recurrent pouchitis (CP) is the most impor-
tant long-term complication leading to poor function fol-
lowing ileal pouch-anal anastomosis for ulcerative colitis.
Antibiotic administration reduces symptoms of pouchitis
indicating that bacteria have a role in pathogenesis [45,
46]. The stool microbiota of patients with pouchitis and
of familial adenomatous polyposis patients has been shown
to be markedly diﬀerent [47]. PCR/TTGE proﬁles of the
stool microbiota of familial adenomatous patients (n = 14)
clustered at the 80% level of similarity, whereas those of
pouchitis patients (n = 17) were disparate. The results of
FISH analysis showed that bacteria not commonly present
in human faeces, nor in the stool of familial adenomatous
polyposis patients, comprised about 50% of the stool micro-
biota of untreated pouchitis patients. Antibiotic treatment
reduced the proportion of these unknown bacteria in the
stool of pouchitis patients. Therefore, chronic or recurrent
pouchitis was found to be associated with a microbiota that
contained bacteria not commonly associated with human
faeces or FAP pouches. Clostridium perfringens was detected
(comprising about 30% of the total bacterial community),
by quantitative PCR, among these less common bacteria in
symptomatic pouches of 10 out of 17 (58.8%) CP patients.
This species was not detected in the same pouches when
asymptomatic. C. perfringens was detected in some normal
pouches (no inﬂammation), but in numbers about 30-
fold lower than in pouchitis. [47; Tannock and Thompson-
Fawcett, unpublished data]. Other studies have also reported
the detection of C. perfringens in pouchitis samples from
UC patients. For example, Ruseler-van Embden et al [48].
analyzed the bacterial composition of the ileal reservoir from
patients that had undergone a restorative proctocolectomy
either for ulcerative colitis (n = 12) or familial adenomatous
polyposis (n = 2). The study was carried out at least
one year after the surgery and ﬁve patients were diagnosed
with pouchitis. Two fecal samples were collected from each
subject of the pouch control group (n = 9) with an
interval of at least two months. Plate counts showed large
diﬀerences in the anaerobic bacterial composition between
two samples taken at diﬀerent times suggesting the non-
inﬂamed pouch had a bacterial community of unstable
composition. Compared to the control group, stool from
pouchitis patients contained a larger number of Clostrid-
ium perfringens. Gosselink et al [49]. Monitored the fecal
microbiota of patients diagnosed with ulcerative colitis and
having undergone a pouch construction (n = 13). The aim
of this study was to compare the eﬀect of two antibiotics,
metronidazole and ciproﬂoxacin, on the fecal microbiota at
diﬀerent times. The bacteriological content of the pouch was
analyzed at the beginning of an inﬂammatory episode before
antibiotic treatment, during treatment with ciproﬂoxacin or
metronidazole, and during pouchitis-free periods. Higher
numbers of C. perfringens and hemolytic strains of E.
coli were observed during pouchitis episodes in 50% of
the patients. Administration of metronidazole eradicated
the Clostridium perfringens. Treatment with ciproﬂoxacin
inhibited not only the growth of Clostridium perfringens
but also that of coliforms, including hemolytic strains
of Escherichia coli. Taken together, these results oﬀer the
possibility that C. perfringens is the aetiolgical agent of
pouchitis in some patients. The absence of C. perfringens
in non-inﬂamed pouches (antibiotic administration) but
its presence in inﬂamed pouches (no antibiotic) probably
satisﬁes Koch’s third postulate (“the isolated microbe, when
administered to humans or animals must cause disease”) in
modiﬁed form.
Duﬀy et al. [50] compared the pouch bacterial content
from ulcerative colitis (n = 10) and familial adenomatous
polyposis (n = 7) patients. None of the patients had had a
previous episode of pouch inﬂammation. Sulphate-reducing
bacteria were exclusively detected in pouches of ulcerative
colitis patients. Ohge et al. [51]) have also shown anInternational Journal of Inﬂammation 7
associationbetweensulphate-reducingbacteriaandpouches.
Sulphate-reducing bacteria were detected in higher numbers
in active pouchitis patients (n = 8) in comparison to
patients without a history of pouchitis (n = 8), patients
with past episode(s) of pouchitis (n = 18), patients having
an ongoing antibiotic treatment for pouch inﬂammation
(n = 11) and familial adenomatous polyposis patients
(n = 5). The authors observed that this particular group
of bacteria was sensitive to metronidazole or ciproﬂoxacin
treatment.
4.3. Changes in the Proportions of Phylogenetic Groups
Comprising the Microbiota. A decrease in the number of
phylotypes (reduced biodiversity) has been reported in
relation to the fecal community of CD patients [52–56].
Scanlan et al.[53], for example, reported that they failed
to detect members of clostridial cluster IV in 27% of CD
fecal samples (PCR) but all control samples contained these
bacteria (P<. 0001). Taken together, the results of these
studies showed a quantitative and a qualitative (biodiversity)
reduction in representation of the Firmicutes phylum, and
particularly clostridial cluster IV members in the feces of CD
patients. This phylogenetic group contains several butyrate
producingbacteria,suchas Faecalibacteriumprausnitzii [55].
Butyrate and other short chain fatty acids are believed to be
important sources of energy for colonic epithelial cells and
may have anti-inﬂammatory properties, as well as improving
barrier function of the bowel epithelium [57–60]. Hence, the
decrease in butyrate-producing bacteria in the colon might
have an overall detrimental eﬀect on the colonic mucosa.
The major ﬁnding of metagenomic studies to date has been,
therefore,thereducedbiodiversityofthemicrobiota.Itisnot
clearwhetherthereducedbiodiversityinitiatesinﬂammatory
bowel diseases, perpetuates the diseases, or is a result of
the diseases. Nor can a change in the composition of the
faecal microbiota (representing the rectum) explain CD
lesions in the small bowel. A reduction in biodiversity has
been reported for both CD and UC patients which suggests
that the changes in microbiota composition are due to the
inﬂamed state of the bowel. The pathology and immunology
and pathogenesis of CD and UC are distinctly diﬀerent
and it will be surprising if the bacterial aetiology, should
there be one, is the same for both diseases. Much ingenious
experimentation will be required to end speculation about
these changes and to produce knowledge of beneﬁt to
medical practitioners and their patients.
5. Conclusions
Improvements to the quality of microbiological investiga-
tions of Crohn’s disease and ulcerative colitis patients will
rely on the more careful selection of patients (perhaps
aided by human genotyping because of the variety of
genetic polymorphisms associated with Crohn’s disease),
the recruitment of newly diagnosed and untreated patients,
and greater attention to the way in which specimens to be
used in microbiological investigations are collected. Overall,
more thoughtful planning of studies aimed at analysis and
comparison of commensal communities are needed in order
to improve microbiological studies in Crohn’s disease and
ulcerative colitis. Analysis of the microbiota of CD and
UC patients has so far resulted in diverging views of the
importance of particular bacteria in the pathogenesis of
inﬂammatory bowel diseases. Nevertheless, strong cases for
the involvement of adherent/invasive E. coli in ileal lesions of
CD are building, and for the role of C. perfringens in some
cases of pouchitis in ulcerative colitis patients.
Reduced biodiversity of the microbiota in CD seems,
however, to be the current popular choice of aetiological
signiﬁcance, especially since it provides the opportunity to
develop probiotic strains of F. prausnitzii or other butyric
acid-producing bacteria. Implantation or enrichment (by
concurrent prebiotic administration) of a cultivated strain
in the inﬂamed bowel seems an unlikely proposition since
the prevailing intestinal conditions associated with disease
have apparently led to the observed reduction or elimination
of the species. Moreover, inﬂamed mucosa seems to have
impaired ability to utilize butyrate [61]. Culture super-
natants of F. prausnitzii and some other butyrate-producing
bacteriaappeartocontainanti-inﬂammatorysubstancesthat
might be puriﬁed and used to treat patients. Detection and
testing of these presumptive anti-inﬂammatory substances
relies on the use of experimental animal models of colitis
and it is not clear yet whether the research can be translated
to treat human patients. Meta-analysis of seven studies that
testedtheeﬀectofmaintenancetreatmentwithstandardpro-
biotics (Lactobacillus rhamnosus GG, Escherichia coli Nissle
1917, VSL#3, Saccharomyces boulardii) among patients with
Crohn’s disease in remission did not demonstrate any beneﬁt
of probiotic treatment [62]. Elahi et al. [63], conducted
a meta-analysis of ﬁve trials on the eﬀect of probiotics
on pouchitis (acute, chronic, and recurrent remission).
Four of these studies (conducted by the same research
group in each case) utilized the multi-strain (Lactobacillus
casei, Lactobacillus plantarum, Lactobacillus acidophilus, Lac-
tobacillus delbrueckii subspecies bulgaricus, Biﬁdobacterium
longum, Biﬁdobacterium breve, Biﬁdobacterium infantis,a n d
Streptococcus thermophlus) probiotic product VSL#3. The
outcome of interest in the meta-analysis was for pouchitis
deﬁned as a pouchitis disease activity index of >7.0. Pooling
of the results from ﬁve trials yielded an odds ratio of 0.04
(95% conﬁdence interval 0.01–0.14, P<. 0001) in the
probiotic group relative to the placebo group. These kinds of
results continue to encouragethe continuing development of
probiotic therapies.
An alternative approach may be to gain information
about potent antigens associated with the bowel microbiota
that drive the inﬂammatory response. Treatment options
would then be to selectively use novel or extant antibiotics
to reduce the fraction of the microbiota producing the most
potent antigens, or to derive drugs that would eﬀectively
block signaling pathways stimulated by these antigens.
After at least twenty years interest in the microbiology of
inﬂammatory bowel diseases without signiﬁcant accrual of
knowledge that can be translated to improved treatments
for patients, new thinking and new research approaches are
clearly indicated.8 International Journal of Inﬂammation
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